BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.
No risks detected for BMRN from our risk checks.
Excellent balance sheet with reasonable growth potential.
Share Price & News
How has BioMarin Pharmaceutical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BMRN has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BMRN underperformed the US Biotechs industry which returned 6.5% over the past year.
Return vs Market: BMRN underperformed the US Market which returned 10.5% over the past year.
Price Volatility Vs. Market
How volatile is BioMarin Pharmaceutical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StAre Investors Undervaluing BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) By 23%?
1 month ago | Simply Wall StDoes BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) CEO Pay Reflect Performance?
2 months ago | Simply Wall StIntroducing BioMarin Pharmaceutical (NASDAQ:BMRN), The Stock That Dropped 10% In The Last Five Years
Is BioMarin Pharmaceutical undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BMRN ($91) is trading below our estimate of fair value ($112.77)
Significantly Below Fair Value: BMRN is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: BMRN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: BMRN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BMRN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BMRN is overvalued based on its PB Ratio (5.3x) compared to the US Biotechs industry average (3x).
How is BioMarin Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 24 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BMRN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: BMRN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BMRN's is expected to become profitable in the next 3 years.
Revenue vs Market: BMRN's revenue (16.5% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: BMRN's revenue (16.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BMRN's Return on Equity is forecast to be low in 3 years time (17.3%).
How has BioMarin Pharmaceutical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BMRN is currently unprofitable.
Growing Profit Margin: BMRN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BMRN is unprofitable, but has reduced losses over the past 5 years at a rate of 15% per year.
Accelerating Growth: Unable to compare BMRN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BMRN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (66.2%).
Return on Equity
High ROE: BMRN has a negative Return on Equity (-1.38%), as it is currently unprofitable.
How is BioMarin Pharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: BMRN's short term assets ($1.9B) exceed its short term liabilities ($493.7M).
Long Term Liabilities: BMRN's short term assets ($1.9B) exceed its long term liabilities ($990.0M).
Debt to Equity History and Analysis
Debt Level: BMRN's debt to equity ratio (27.4%) is considered satisfactory.
Reducing Debt: BMRN's debt to equity ratio has reduced from 43.5% to 27.4% over the past 5 years.
Inventory Level: BMRN has a high level of physical assets or inventory.
Debt Coverage by Assets: BMRN's debt is covered by short term assets (assets are 2.2x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BMRN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BMRN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is BioMarin Pharmaceutical's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BMRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate BMRN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BMRN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BMRN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BMRN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jean-Jacques Bienaimé (66yo)
Mr. Jean-Jacques Bienaime, MBA, has been the Chief Executive Officer of Biomarin Pharmaceutical Inc. since June 2005. He served as Director at Vital Therapies, Inc. since September 2013 to October 10, 2018 ...
CEO Compensation Analysis
Compensation vs Market: Jean-Jacques's total compensation ($USD15.63M) is above average for companies of similar size in the US market ($USD10.82M).
Compensation vs Earnings: Jean-Jacques's compensation has been consistent with company performance over the past year.
|Chairman & CEO||14.8yrs||US$15.63m||0.28% $46.4m|
|President of Global Manufacturing & Technical Operations||0yrs||US$4.43m||0.065% $10.7m|
|Executive VP & Chief Commercial Officer||7.3yrs||US$4.55m||0.034% $5.6m|
|President of Worldwide Research & Development||3.3yrs||US$5.78m||0.038% $6.2m|
|Senior Advisor||0.08yrs||US$4.52m||0.0035% $580.0k|
|Senior VP of Finance||0.08yrs||no data||0.011% $1.8m|
|Chief Scientific Strategy Officer||0yrs||no data||no data|
|Vice President of Investor Relations||0yrs||no data||no data|
|Executive VP||16.1yrs||US$2.71m||0.038% $6.3m|
|Senior VP & Chief Compliance Officer||0yrs||no data||no data|
Experienced Management: BMRN's management team is seasoned and experienced (5.3 years average tenure).
|Chairman & CEO||14.8yrs||US$15.63m||0.28% $46.4m|
|Lead Independent Director||4.7yrs||US$544.66k||0.042% $6.9m|
|Independent Director||14.2yrs||US$489.91k||0.017% $2.7m|
|Independent Director||4.1yrs||US$479.91k||0.0076% $1.2m|
|Independent Director||17.6yrs||US$500.66k||0.024% $3.9m|
|Independent Director||14.7yrs||US$489.91k||0.0094% $1.5m|
|Independent Director||12.7yrs||US$481.91k||0.011% $1.7m|
|Independent Director||3.6yrs||US$478.66k||0.0075% $1.2m|
|Independent Director||5.9yrs||US$478.66k||0.0055% $901.2k|
|Independent Director||2.4yrs||US$492.91k||0.0018% $290.0k|
Experienced Board: BMRN's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
BioMarin Pharmaceutical Inc.'s company bio, employee growth, exchange listings and data sources
- Name: BioMarin Pharmaceutical Inc.
- Ticker: BMRN
- Exchange: NasdaqGS
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$16.385b
- Shares outstanding: 179.63m
- Website: https://www.biomarin.com
Number of Employees
- BioMarin Pharmaceutical Inc.
- 770 Lindaro Street
- San Rafael
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BMRN||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jul 1999|
|BM8||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jul 1999|
|BMRN||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||Jul 1999|
|0HNC||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jul 1999|
|BM8||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||Jul 1999|
|BMRN *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jul 1999|
|B1MR34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH 2 REPR 1 COM||BR||BRL||Jan 2020|
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder; and Firdapse for lambert eaton myasthenic syndrome. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector drug development candidate in patients with severe hemophilia A; and vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/27 00:43|
|End of Day Share Price||2020/02/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.